床旁抗 CD19 CAR-T 细胞疗法治疗复发/难治性滤泡性淋巴瘤

Patients with relapsed/refractory follicular lymphoma (R/R-FL) often require multiple treatment lines.

We performed a phase 1b/2 single-center clinical trial of autologous point-of-care anti-CD19 chimeric antigen receptor (CAR) T-cells in R/R-FL patients treated patients with 2 treatment lines. All 26 patients enrolled received CAR T-cell infusion at a median of 11 days after leukapheresis.

Seventy-seven percent of patients had POD24. At enrollment, disease stage was III-IV in 85% of the patients, 77% had high-risk FLIPI score, and 77% had progressive disease. Grade III-IV cytokine release and immune effector cell-associated neurotoxicity syndromes occurred in 12% and 16% of the patients, respectively.

Overall response rate at 1-month was 88%. The median follow-up was 15. 4 months. One-year overall and progression-free survival were 100% and 63%, respectively.

In conclusion, point-of-care CAR T-cell, manufactured within 11 days, induced a high response rate with an acceptable safety profile in patients with high-risk R/R-FL.